Recombinant .alpha.-galactosidase A therapy for Fabry disease
US5658567A · kind A · utility
34Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 22, 1993 |
| Grant date | Aug 19, 1997 |
| Priority date | — |
| Expiry date | Nov 22, 2013 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Fabry disease results from an X-linked deficiency in the enzyme .alpha.-galactosidase A. The present invention is directed to recombinant human .alpha.-galactosidase A and provides baculovirus expression vectors and recombinant virus that provide stable expression of extracellular and intracellular levels of this enzyme in an insect cell culture. The recombinant-derived enzyme can be used in enzyme replacement therapy to treat Fabry patients. Composition useful in therapeutic administration of .alpha.-galactosidase A are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.